Upcoming FDA advisory committee meetings
Executive Summary
Oncology Drugs Advisory Committee will meet April 19, 8:30 a.m. at the Parklawn Building to discuss use of Bristol-Myers' ifosfamide for use in combination with other approved cytotoxic drugs for treatment of testicular cancer; Dermatologic Drugs Advisory Committee's April 26 meeting (8:30 a.m. at Parklawn) will address adverse effects of Roche's Accutane (isotretinoin); Pulmonary-Allergy Drugs Advisory Committee agenda at April 28-29 meeting includes the new drug evaluation review process, use of caffeine for apnea of prematurity, and data supporting pediatric use of inhaled albuterol.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.